Acta Med. 2021, 64: 8-14
https://doi.org/10.14712/18059694.2021.2
The Effects of Ranitidine Treatment on the Risk of Necrotizing Enterocolitis in Preterm Infants: A Case-Control Study
References
1. SC, Ching Y, Yu D, Carpenter J, et al. Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg 2009; 44(6): 1072–5; discussion 5–6.
<https://doi.org/10.1016/j.jpedsurg.2009.02.013>
2. BL, Modi BP, Jaksic T, Caplan MS. New Medical and Surgical Insights Into Neonatal Necrotizing Enterocolitis: A Review. JAMA Pediatr 2017; 171(1): 83–8.
<https://doi.org/10.1001/jamapediatrics.2016.2708>
3. Alganabi M, Lee C, Bindi E, Li B, Pierro A. Recent advances in understanding necrotizing enterocolitis. F1000Res 2019; 8: F1000 Faculty Rev-107.
4. M, Moore SW, Sidler D, Kirsten GF. Long-term outcome of surgically managed necrotizing enterocolitis in a developing country. Pediatr Surg Int 2010; 26(4): 355–60.
<https://doi.org/10.1007/s00383-010-2583-8>
5. Q, Lv Z, Xu W, et al. Short-term surgical outcomes of preterm infants with necrotizing enterocolitis: A single-center experience. Medicine (Baltimore) 2016; 95(30): e4379.
<https://doi.org/10.1097/MD.0000000000004379>
<PubMed>
6. H, Mao S, Shi L, Tou J, Du L. Clinical characteristic comparison of low birth weight and very low birth weight preterm infants with neonatal necrotizing enterocolitis: a single tertiary center experience from eastern China. Pediatr Surg Int 2018; 34(11): 1201–7.
<https://doi.org/10.1007/s00383-018-4339-9>
7. G, Jape G, Rao S, Patole S. Benefits of probiotics in preterm neonates in low-income and medium-income countries: a systematic review of randomised controlled trials. BMJ Open 2017; 7(12): e017638.
<https://doi.org/10.1136/bmjopen-2017-017638>
<PubMed>
8. J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011; 364(3): 255–64.
<https://doi.org/10.1056/NEJMra1005408>
<PubMed>
9. AL, Ruuska T, Karikoski R, et al. A randomized, controlled study of prophylactic ranitidine in preventing stress-induced gastric mucosal lesions in neonatal intensive care unit patients. Crit Care Med 1997; 25(2): 346–51.
<https://doi.org/10.1097/00003246-199702000-00025>
10. TM, Whittam TS. Variation in acid resistance among enterohaemorrhagic Escherichia coli in a simulated gastric environment. J Appl Microbiol 2007; 102(2): 352–62.
<https://doi.org/10.1111/j.1365-2672.2006.03099.x>
11. TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol 2005; 96(2): 94–102.
<https://doi.org/10.1111/j.1742-7843.2005.pto960202.x>
12. MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104(Suppl 2): S10–6.
13. RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol 2010; 26(1): 31–5.
<https://doi.org/10.1097/MOG.0b013e328333d781>
14. RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community- acquired pneumonia in children. Pediatrics 2006; 117(5): e817–20.
<https://doi.org/10.1542/peds.2005-1655>
15. G, Canani RB, Passariello A, Caoci S, De Curtis M. Inhibitors of gastric acid secretion drugs increase neonatal morbidity and mortality. J Matern Fetal Neonatal Med 2012; 25(Suppl 4): 85–7.
<https://doi.org/10.3109/14767058.2012.714975>
16. S. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis: a case of excessive collateral damage? Pediatrics 2006; 117(2): 531–2.
<https://doi.org/10.1542/peds.2005-2230>
17. G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129(1): e40–5.
<https://doi.org/10.1542/peds.2011-0796>
18. K, Athalye-Jape G, Rao S, Patole S. Association of inhibitors of gastric acid secretion and higher incidence of necrotizing enterocolitis in preterm very low-birth-weight infants. Am J Perinatol 2013; 30(10): 849–56.
19. N, Dhayade A, Mohamed AL, Chaudhari TV. Morbidity and Mortality in Preterm Infants following Antacid Use: A Retrospective Audit. Int J Pediatr 2016; 2016: 9649162.
<https://doi.org/10.1155/2016/9649162>
<PubMed>
20. T, Thompson Z, Carver JD. Factors that influence mesenteric artery blood flow velocity in newborn preterm infants. J Perinatol 2006; 26(8): 493–7.
<https://doi.org/10.1038/sj.jp.7211551>
21. Z, Milisic E, Jonuzi A, Terzic S, Zvizdic D. The contribution of morphine sulfate to the development of necrotizing enterocolitis in preterm infants: a matched casecontrol study. Turk J Pediatr 2019; 61(4): 513–9.
<https://doi.org/10.24953/turkjped.2019.04.007>
22. SM, Spitzer AR, Effken JA, Dodd E, Halpern M, McGrath JM. Discrimination of GutCheck(NEC): a clinical risk index for necrotizing enterocolitis. J Perinatol 2014; 34(6): 468–75.
<https://doi.org/10.1038/jp.2014.37>
<PubMed>
23. A, Shah PS. Transfusion associated necrotizing enterocolitis: a meta-analysis of observational data. Pediatrics 2012; 129(3): 529–40.
<https://doi.org/10.1542/peds.2011-2872>
24. EK, Lazrek M, Schuffenecker I, et al. Necrotizing Enterocolitis Cases Associated with Nosocomial Enterovirus Transmission in a Neonatal Unit. Pediatr Infect Dis J 2018; 37(9): 954–7.
<https://doi.org/10.1097/INF.0000000000001928>
25. RNS, Santos VS, Ribeiro-Junior RF, et al. Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study. BMC Infect Dis 2017; 17(1): 375.
<https://doi.org/10.1186/s12879-017-2482-x>
<PubMed>
26. MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33(1): 179–201.
<https://doi.org/10.1016/S0031-3955(16)34975-6>
<PubMed>
27. S, Rees CM, Hall NJ. Current Research on the Epidemiology, Pathogenesis, and Management of Necrotizing Enterocolitis. Neonatology 2017; 111(4): 423–30.
<https://doi.org/10.1159/000458462>
28. R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006; 117(2): e137–42.
<https://doi.org/10.1542/peds.2005-1543>
29. HC, Su BH, Chen AC. H2-blocker therapy and necrotizing enterocolitis for very low birth weight preterm infants. Pediatrics 2006; 118(4): 1794–5; author reply 5–6.
<https://doi.org/10.1542/peds.2006-1607>
30. A, Galanis P, Bartsocas C, Sparos L, Velonakis E. H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr Neonatol 2013; 54(2): 141–2.
<https://doi.org/10.1016/j.pedneo.2013.01.011>
31. M, Fleming P. Question 1: does the use of ranitidine increase the risk of NEC in preterm infants? Arch Dis Child 2014; 99(4): 390–2.
<https://doi.org/10.1136/archdischild-2013-304973>
32. VS, Freire MS, Santana RNS, Martins-Filho PRS, Cuevas LE, Gurgel RQ. Association between histamine-2 receptor antagonists and adverse outcomes in neonates: A systematic review and meta- analysis. PloS One 2019; 14(4): e0214135.
<https://doi.org/10.1371/journal.pone.0214135>
<PubMed>
33. DS, Abdel-Latif ME, Jones LJ, Lui K, Osborn DA. Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants. Cochrane Database Syst Rev 2019; 7: CD011785.
34. N, van de Graaf RA, de Jonge RCJ, Reiss IKM, Vermeulen MJ. Risk factors for necrotizing enterocolitis in neonates: a systematic review of prognostic studies. BMC Pediatrics 2017; 17(1): 105.
<https://doi.org/10.1186/s12887-017-0847-3>
<PubMed>
35. Z, Heljic S, Firdus A, Jonuzi A, Zvizdic D. Relationship of nosocomial infections with the development of necrotizing enterocolitis in preterm infants. Mater Sociomed 2014; 26(1): 4–6.
<https://doi.org/10.5455/msm.2014.26.4-6>
<PubMed>
36. CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13(12): 1110–6.
<https://doi.org/10.1097/00006454-199412000-00008>
37. PL, Begg MD, Larson E, Della-Latta P, Allen A, Saiman L. Risk factors for late onset gram-negative sepsis in low birth weight infants hospitalized in the neonatal intensive care unit. Pediatr Infect Dis J 2006; 25(2): 113–7.
<https://doi.org/10.1097/01.inf.0000199310.52875.10>
38. S, McIntyre J. The use of unlicensed and off-label medicines in the neonate. Semin Fetal Neonatal Med 2005; 10(2): 115–22.
<https://doi.org/10.1016/j.siny.2004.11.003>
39. J. Gastrointestinal maturation and implications for infant feeding. Early Hum Dev 2007; 83(12): 767–75.
<https://doi.org/10.1016/j.earlhumdev.2007.09.009>
40. AK, Bhattacharya SK, Mediratta PK, Sharma KK. Possible role of histamine receptors in the central regulation of immune responses. Indian J Physiol Pharmacol 2000; 44(2): 153–60.
41. TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998; 102(10): 1866–73.
<https://doi.org/10.1172/JCI3692>
<PubMed>



